{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:59:15Z","timestamp":1770141555765,"version":"3.49.0"},"reference-count":13,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Objective: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) may affect the course and outcome of COVID-19, but withholding them could permit disease activity. This study aimed to understand the course of COVID-19 in unvaccinated patients with MS on disease-modifying therapies. Subjects and Methods: This descriptive study examined the course of COVID-19 among infected patients with MS followed up at a large tertiary center in Kuwait between March 1, 2020, and March 1, 2021. All subjects were outpatients at the time of data collection. Results: We studied 51 patients with MS confirmed to be infected with SARS-CoV-2 using real-time polymerase chain reaction. Of these patients, 33\/51 were female, median age was 35 years (IQR 27\u201339 years), median Expanded Disability Status Scale score was 1.5 (IQR zero\u20133), and 47\/51 had RRMS. B-cell-depleting agents (ocrelizumab and rituximab) were given to 19 patients, another 19 were on immune cell traffickers (fingolimod and natalizumab), and 13 were on other DMT treatments (alemtuzumab, cladribine, interferon-beta, dimethyl fumarate, and teriflunomide). 43\/51 of these patients experienced mild COVID-19, not requiring hospitalization. None of the subjects experienced MS relapses during infection. Two patients on rituximab had a moderate course of the illness, which required hospitalization for oxygen support, but did not need mechanical ventilation; the rest of the subjects remained asymptomatic. Conclusions: These findings suggest that DMT may not adversely affect the course of COVID-19 in MS patients; however, patients on B-cell-depleting agents trended toward a worse outcome. <\/jats:p>","DOI":"10.1159\/000530764","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T21:00:51Z","timestamp":1689109251000},"page":"143-148","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies"],"prefix":"10.1159","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-1980","authenticated-orcid":false,"given":"Suhail","family":"Al-Shammri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeti","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhail","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.11.005"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102185"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2581"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00756-y"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9124067"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/eje-18-0736"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102822"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(20)30183-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0301"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0688"}],"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/mpp\/article-pdf\/32\/2\/143\/3960392\/000530764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/mpp\/article-pdf\/32\/2\/143\/3960392\/000530764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:27:41Z","timestamp":1745422061000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000530764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,11]]},"published-print":{"date-parts":[[2023,7,12]]}},"URL":"https:\/\/doi.org\/10.1159\/000530764","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"value":"1011-7571","type":"print"},{"value":"1423-0151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}